—Millendo Therapeutics, an Ann Arbor-based biopharmaceutical company developing treatments for rare diseases, has initiated a Phase 2b/3 clinical study investigating livoletide (AZP-531) in patients with Prader-Willi syndrome.
The study will evaluate the safety and efficacy of the drug on food-related behaviors—primarily hyperphagia, the excessive hunger which is a hallmark of the disease—in Prader-Willi patients. The study, called Zephyr, aims to recruit 150 patients from up to 40 clinical sites in the United States and Europe. For more information on the study, click here.
UNDERWRITERS AND PARTNERS